Unresectable Gastroesophageal Junction Adenocarcinoma Withdrawn Phase 1 / 2 Trials for Irinotecan (DB00762)

IndicationStatusPhase
DBCOND0113409 (Unresectable Gastroesophageal Junction Adenocarcinoma)Withdrawn1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03739801MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction AdenocarcinomaTreatment